Jumlah leukosit (x109/L
KESIMPULAN DAN SARAN
Hasil penelitian ini menunjukan bahwa aktifitas faktor VII pada sepsis lebih rendah bermakna dibanding orang normal, dan memerlukan penelitian jauh kedepan untuk mengetahui mekanisme mengapa FVII menurun aktifitasnya pada sepsis.
Walaupun mungkin dapat digunakan sebagai salah satu pertanda DIC, sampai saat ini belum dapat dipakai saran dan diagnostik.
KEPUSTAKAAN
1. Abraham E.Tissue faktor inhibition and clinical trial result of tissue faktor pathway inhibitor in sepsis. Crit care med. 2000 ; 28(suppl):S31 – 3.
2. Astiz ME, Rackow EC. Septic shock. The lancet 1998 ; 351 : 1501 – 5.
3. Bauer KA, Rosenberg RD. Control of coagulant reaction. In : Beutler E, Lictman MA, Coller BS, Kipps TJ, Eds. Williams Hematology.5th ed. New York : McGraw-Hill, 1995 : 1139 – 251
4. Bauner KA. Laboratory markers of coagulation activation. In : McArthur JR, Lee SH, Wong JEL, et al. Eds. Proceeding of the 26th Congress of the International Society of Haemotology ; 1996 August 25 – 29 ; Singapore, 1996 : 435 – 7.
5. Bough RJ, Broze Jr GJ, Krishnaswamy S. Regulation of Extrinsic Pathway Faktor Xa Formation by Tissue Faktor Pathway Inhibitor. J Biol Chem 1998;273 :4378 – 86.
6. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein c for severer sepsis. N Eng J Med 2001 ; 344 : 699 - 709
7. Bithell TC. Blood coagulation. In : Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, Editor. Wintrobe’s Clinical Hematology. Volume 1, 9th ed. Philadelphia : Lea & Febiger, 1993 : 566 – 615.
8. Bithell TC. Platelets and megakaryocytes. In : Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, Editors. Wintrobe’s Clinical Hematology. Volume 1,9th ed. Philadelphia : Lea & Febriger, 1993 : 511 – 39.
9. Bithell TC. The physiology of primary hemostasis. In : Lee GR, Bithell TC, Foester J, Athens JW, Lukens JN, Editors. Wintrobe’s Clinical Hematology. Volume 1, 9th ed. Philadelphia : Lea & Febiger, 1993 : 540 – 65.
10. Bithell TC. Thrombosis and antithrombotic theraphy. In : Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, Editor. Winstrobe’s Clinical Hematology : 1,9th ed. Philadelphia : Lea & Febiger, 1993 : 1515 – 51.
11. Braundwald E. Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Sepsis and septic shock. In : Harrison’s manual of medicine. New York : McGraw-Hill, 2002 : 129 – 32.
12. Brozovic M, Mackiel. Investigation of a bleeding tendency. In : Dacie JV, Lewis SM, eds. Practical Haemotology. Seventh ed. London : Chruchill Livingtone, 1993 : 293 – 318.
13. Brozovic M. Investigation of acute haemostatic failure. In : Dacie JV, Lewis SM, eds. Practical Haemotology. Seventh ed. London : Chruchill Livingtone, 1993 : 279 – 84.
14. Brozovic M. Investigation of Haemostasis. In : Dacie SJV, Lewis SM, editors. Practical Haemotology. Seventh ed. London : Chruchill Livingtone, 1993 : 279 – 84.
15. Burstein SA, Breton-Gorius J. Megakaryopoiesis and platelet formation. In : Beutler E, Lichtman MA, Coller BS, Kipps TJ, Eds. Williams Hematology. 5th ed. New York : McGraw-Hill, 1995 : 1149 – 60
16. Cate HT. pathophysiology of disseminated intravascular coagulation in sepsis. Crit care med 2000 ; 28 (suppl) : S9 – S11
17. Chong BH. The “New” coagulation cascade. Proceeding of the 4th Malaysian Natinonal Heamotology Scientific Meeting, 2002 Mar 15-17; Penang, Malaysia.
18. Eichinger S, Mannucci PM, Tradati F, et al. Determinant of plasma faktor VIIa Levels in Humans. Blood 1995 ; 86 : 3021 – 5.
19. Esmon CT. introduction : are natural anticoagulants candidates for modulating the inflammatory response to endotoxin ? Blood 2000;95 : 1113 – 6.
20. Evans TW, Smithies M. ABC of intensive care Organ dysfunction. BMJ 1999 ; 318 : 1606-9.
21. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A. Marey A, Lestavel P. Septic shock, multiple organ failure and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 1992 ; 101 (3), 816-23
22. Glauser MP. Pathophysiologic basic of sepsis : Consideration for future strategies of intervention. Crit care med 2000; 28(suppl) : S4 – 8
23. Goodnight SH, Hathaway WE. Disorder of haemostatis & thrombosis a clinical quide. Second ed. New York : McGraw-Hill, 2001
24. Hack CE. Tissue faktor pathaway of coagulation in sepsis. Crit care med 2000 ; 28(suppl) : S25-30.
25. Hayes TE, Pike J, Tracy RP. Faktor VII Assays. Arch Pathol Lab Med 1993 ;117 : 52-7.
26. Jackson CM. Biochemistry of prothrombin activation. In : Bloom AL, Thomas DP, eds. Haemostasis and thrombosis. London : Churchill Livingtone, 1981 : 140 -62.
27. Jonge ED, Dekkers PEP, Creasey AA, et al. Tissue faktor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 200 ;95 : 1124 – 9.
28. A. Laffan MA, Manning RA. Investigation of haemostasis. In : Lewis SM, Bain BJ, Bates I, eds. Practical Haematology 9th edition. London : Churc hill Livingtone, 2001 : 339 – 90.
29. Lammle B, Griffin JH. Formation of the fibrin clot;the balance of procoagulant and inhibitory factors. In : Hoffbrand AV, Lasch HG, Nathan DG, et al, Eds Clinics in haemotology ; 14;2. philadelphia : W.B. Saunders Company, 1985 : 281 – 342.
30. Levi M, Jonge ED, Poll TVD, Cate HT. Novell approaches to the management of disseminated intravascular coagulation. Crit care med 2000;28(suppl) : 20-4.
31. Mann KG, Gaffney D, Bovill EG. Molecular biology, biochemistry, and lifespan of plas ma coagulation faktor. In : Beutler E, Lichtman MA, Coller BS, Kipps TJ, Eds Williams hematology. 5th ed. New York : McGraw-Hill, 1995 : 1206 - 26 32. Marcus AJ. Platelets and their disorders. In : Ratnoff OD, Forbes CD, editors.
Disorders of hemostasis. Philadelphia : Saunders, 1996 : 79 – 137 33. Martin GS. The complex Role of cagulation in pathophysiology of sepsis.
Proceeding of the 30th International educational and scientific symposium of the society of critical care medicine ; Day 1 –February 10, 2001
http://www.medscape.com/medscape/cno/2001/SCCM/Story.cfm?story_id=2 081
34. Mesters RM, Mannucci PM, Coppola R, et al. Faktor VIIa and Antithrombin III Activity During Severe Sepsis and Septic Shock in Neutropenic Patient. Blood 1996;88:881-6.
35. Miller JL. Blood coagulation and fibrinolysis. In : Henry JB. Ed. Clinical
diagnosis & management by laboratory methods. 18th ed. Philadelphia : W.B. Saunders Company, 1991 : 734-57.
36. Moore DJ. Pathogenesis and management of septic shock. The Dalhousie Medical Journal, December 1997
37. Morrissey JH. Plasma faktor VIIa : Measurement and potential clinical significance. Haemostasis 1996 ; 26 (suppl 1) : 66 – 71.
38. Opal SM. Sepsis. In : Scientific American Medicine. Copyright© 1999, Scientific American, Inc.
39. Peterson LC. Effect of Ca2+ on the structure and function of faktor VIIa. Haemostasis 1996;26 (suppl 1) : 40 – 4.
40. Pittet D, Harbarth, S, Suter PM, et al. impact of immunomodulating theraphy o morbidity in patient with severe sepsis. Am J Repir Crit Care Med
1999;160:852-7.
41. Prentice. Acquired coagulation disorders. In : Hoffbrand AV, Lasch HG, Nathan DG, et al, eds. Clinical in haemotology. Volume 14;Number2. Philadelphia : W.B. Saunders Company, 1985 : 413 – 37
42. Ratnoff OD. Hemostatic defects in liver and biliary tract disease and disorders of vitamin K metabolism. In : Ratnoff OD, Forbes CD, eds. Disorders of hemostasis. Philadelphia : Saunders, 1996 : 422 – 42.
43. Root RK, Jacobs R. Septicemia and septic shock. In : Wilson JD, Braunwald E, Isselbacker KJ, et al. Eds. Harison’s Principles of internal medicine. 12th ed. New York : McGraw-Hill, 1991 : 502-7
44. Saito H. Normal hemostatic mechanisms. In : Ratnoff OD, Forbes CD, editors. Disorders of hemostasis. Philadelphia : Saunder, 1996 : 23 – 52
45. Stove S, Welte T, Magner TO, Kola A, Boutsch W, Khol J. circulating complement proteins in patiens with sepsis or systemic inflammatory response syndrome. Clin and diag. Lab Imunology, 1996 : 3 (2) : 175 – 83. 46. Tapper H, Herwald H. Modulation of hemostatic mechanism in bacterial
infectious diseases. Blood 2000;96 : 2329 – 36.
47. Thomson JM, Poller L. The activated partial thromboplastin time. In : Thomson JM, et. Blood coagulation and haemostasis. 3rd ed. Edinburgh London Melbourne and New York : Churchill Livingtone, 1085 : 301-39. 48. Taylor FB, Eada H, Kinasewitz G. Description of compresented and
uncompensated dessiminated intravascular coagulation (DIC) response ( non-over and non-over DIC) in baboon models of intravenous and intraperitoneal Eschericia coli sepsis and in the human model of endotoxaemia : Toward a better definition of DIC. Crit care Med; 2000;28;9 (suppl), S 12-9.
49. Van der Pool T, Buller HR, ten Cate H, Wortel CH, Bauser KA, van de Venter SJ, Hack CE, SAuerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis faktor to normal subjects. N.E.J Med : 1990 ; 322 (23), 1622-7.
50. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically III patient with sepsis and septic shock. Seminars in thrombosis and hemostasis 1998 ; 24 : 33 – 44.
51. Warren JR. sepsis. In : Shulman ST, Phair JP, Peterson LR, Warren JR, eds. Infectious diseases. 5th ed. Philadelphia : W.R. Saunders Company, 1997 : 475-89.
52. Zur M, Nemerson Y. Tissue factor pathway of blood coagulation. In : Bloom AL, Thomas DP, eds. Haemostasis and thrombosis. London : Churchill Livingtone, 1981: 124-39.